{"nctId":"NCT02675998","briefTitle":"An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)","startDateStruct":{"date":"2016-01"},"conditions":["Hyperphosphatemia"],"count":219,"armGroups":[{"label":"3mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Tenapanor"]},{"label":"10mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Tenapanor"]},{"label":"Dose Titration","type":"EXPERIMENTAL","interventionNames":["Drug: Tenapanor"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tenapanor","otherNames":["RDX5791, AZD1722"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 to 80 years old\n* Females must be non-pregnant, non-lactating, and either be post-menopausal for at least 12 months, have documentation of irreversible surgical sterilization, or confirm the use of one of the acceptable contraceptive methods.\n* Males must agree to avoid fathering a child and agree to use an appropriate method of contraception\n* Chronic maintenance hemodialysis 3x/week for at least 3 months\n* Kt/V ≥ 1.3 at most recent measurement prior to screening\n* Prescribed and taking at least 3 doses of phosphate binder per day\n* Serum phosphate levels should be between 4.0 and 7.0 mg/dL (inclusive) at screening\n* For randomization in the study, after 1 week wash-out of phosphate binders, subjects must have serum phosphate level of at least 9 mg/dL but below 10 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value\n* For randomization in the study, after 2 or 3 weeks wash-out of phosphate binders, subjects must have serum phosphate level of at least 6 mg/dL but below 10 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value\n\nExclusion Criteria:\n\n* Severe hyperphosphatemia defined as \\>10 mg/dL on Phosphate-binders at any time point during clinical routine monitoring for the 3 preceding months before screening\n* Serum parathyroid hormone \\>1200 pg/mL\n* Persistent metabolic acidosis defined as serum carbon dioxide \\<18 mmol/L from two consecutive measurements during screening and washout periods\n* Clinical signs of hypovolemia at randomization\n* History of inflammatory bowel disease (IBD) or diarrhea predominant irritable bowel syndrome (IBS-D)\n* Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another center during the study period\n* Diarrhea or loose stools during the week before randomization defined as BSFS ≥ 6 and frequency ≥ 3 for 2 or more days\n* Any evidence of or treatment of malignancy within one year, excluding non-melanomatous malignancies of the skin\n* Positive serology with evidence of significant hepatic impairment or WBC elevation according to the Investigator\n* Life expectancy \\< 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Placebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms","description":"Serum phosphorus difference between placebo and tenapanor in the change from the end of the 8 week treatment period to the end of the randomized withdrawal period in Efficacy Analysis Set. The efficacy analysis was pre-defined to be a pooled analysis of all tenapanor treated patients with a minimum of a 1.2 mg/dL decrease in serum phosphorus during the 8-week treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"1.4","spread":"0.23"},{"groupId":"OG003","value":"0.6","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Phosphate During 8-Week Treatment Period","description":"Serum phosphorus difference between baseline (end of washout period) to the end of the 8 week treatment period in ITT analysis set","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"0.17"},{"groupId":"OG001","value":"-1.1","spread":"0.17"},{"groupId":"OG002","value":"-1.1","spread":"0.18"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":74},"commonTop":["Diarrhea"]}}}